Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Apr;9(4):555-564.
doi: 10.1016/j.jacep.2022.11.026. Epub 2023 Feb 22.

Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF)

Dhanunjaya Lakkireddy  1 , Adnan Ahmed  2 , Donita Atkins  2 , Danish Bawa  2 , Jalaj Garg  3 , Jenny Bush  2 , Rishi Charate  2 , Sudha Bommana  2 , Naga Venkata K Pothineni  2 , Rajesh Kabra  2 , Douglas Darden  2 , Scott Koreber  2 , Rangarao Tummala  2 , Chandrashekar Vasamreddy  2 , Peter Park  2 , Sanghamitra Mohanty  4 , Rakesh Gopinathannair  2 , B Woun Seo  5 , Andrea Natale  4 , Robert Kennedy  6
Affiliations
Free article
Multicenter Study

Feasibility and Safety of Intravenous Sotalol Loading in Adult Patients With Atrial Fibrillation (DASH-AF)

Dhanunjaya Lakkireddy et al. JACC Clin Electrophysiol. 2023 Apr.
Free article

Abstract

Background: Inpatient initiation of sotalol is recommended owing to its proarrhythmic effects.

Objectives: The DASH-AF (Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation) trial evaluates the safety and feasibility of intravenous (IV) sotalol, achieving a steady state with maximum QTc prolongation within 6 hours instead of the traditional 5-dose inpatient oral (PO) titration.

Methods: DASH-AF is a prospective, nonrandomized, multicenter, open-label trial consisting of patients who underwent IV sotalol loading dose to initiate rapid oral therapy for atrial arrhythmias. IV dose was calculated based on the target oral dose as indicated by baseline QTc and renal function. Patients' QTc (in sinus) was measured via electrocardiography at 15-minute intervals and after IV loading completion. Patients were discharged 4 hours after first oral dose. All patients were monitored via mobile cardiac outpatient telemetry for 72 hours. The control group was composed of patients admitted for the traditional 5 PO doses. Safety outcomes were assessed in both groups.

Results: A total of 120 patients from 3 centers were enrolled from 2021 to 2022 in the IV loading group (compared with type of AF- and renal function-matched patients in the conventional PO loading cohort). This study demonstrated no significant change in ΔQTc in both groups, with a significantly lower number of patients requiring dose adjustment in the IV arm compared with the PO arm (4.1% vs 16.6%; P = 0.003). This led to potential cost savings of up to $3,500.68 per admission.

Conclusions: The DASH-AF trial shows that rapid IV sotalol loading in atrial fibrillation/flutter patients for rhythm control is feasible and safe compared with conventional oral loading with significant cost reduction. (Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation [DASH-AF]; NCT04473807).

Keywords: IV sotalol; MCOT; QTc; atrial fibrillation; oral loading; torsades de pointes.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures This study was funded by an unrestricted grant from AltaThera Pharmaceuticals. Special thanks to Philips Biotel for their support with the heart monitors in the study. Dr Lakkireddy is consultant for Abbott, Acutus, AltaThera, Boston Scientific, Biosense Webster, and Medtronic. Dr Pothineni has received speaking honorarium from Boston Scientific. Dr Gopinathannair has received consultancy or honoraria from Abbott Medical, Zoll Medical, and Sanofi; and is on the advisory board for Pacemate. Dr Woun Seo was an employee of AltaThera Pharmaceuticals at the time of this study initiation; and is consultant for AltaThera. Dr Natale is consultant for Medtronic, Abbott, Biosense Webster, Boston Scientific, and Acutus. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Comment in

Publication types

Associated data